What is neurofibromatosis?

Neurofibromatosis is a genetic condition that involves abnormal growths on virtually any nerve in the body, including the brain and spinal cord. It is usually diagnosed in childhood and can be inherited from an affected parent in approximately one-half of patients. In the remainder of patients, there is no known previous family history. There is roughly a 50 percent chance that an affected parent will pass on the condition to each child.

What are the physical signs and symptoms of neurofibromatosis?

Patients may begin to experience their first symptoms in early childhood and adolescence. The hormones of puberty and pregnancy can exacerbate symptoms and stimulate tumor enlargement. Patients often present with pigmented birthmarks called café-au-lait spots on their bodies. Fortunately, most symptoms are relatively mild, and patients can have long and fulfilling lives. However, tumors affecting critical nerves can produce loss of vision, hearing, and severe pain. In addition, various neurofibromas can produce changes in soft tissues, producing mild to severe disfigurement.

Who manages and treats neurofibromatosis?

Because neurofibromatosis occurs throughout the body, management and treatment are usually guided by multiple specialists. A specialized neurologist in a multidisciplinary setting (Neurofibromatosis Clinic) serves as the hub for medical management for many patients. Periodic monitoring of neurofibromatosis is required over a lifetime. Skin examinations, developmental assessments in children, evaluation for early puberty in kids, checking for skeletal changes, and eye examinations are required. A genetics consultation is also a necessary part of early management. Periodic exams and MRI studies of the brain may be required during childhood and adolescence to monitor critical areas where there may be growth of tumors.

NF1 vs. NF2 vs. Schwannomatosis

Neurofibromatosis Type 1 (NF1)

Neurofibromatosis 1 (NF1) (also known as von Recklinghausen's disease) is the most common type for this condition. It occurs in 1 in 2,000 to 3,000 individuals. The NF1 gene exists on chromosome 17, creating a specific type of regulatory protein for nerves. A mutation in this gene results in impairment of regulation and leads to uncontrolled cell growth.

Neurofibromatosis Type 2 (NF2)

New guidelines have updated the classification of what was previously known as simply NF2 to more accurately describe the condition.1 NF2-related schwannomatosis (NF2) is the new designation. It is similar in some respect to NF1 where a mutation in a specific gene (NF2 gene) on a different chromosome (chromosome 22) causes uncontrolled cell growth. Aside from affecting a different gene than NF1, it is characterized by specific nervous system tumors including vestibular schwannomas (tumors of the eighth cranial nerve involved in balance and hearing), intracranial and spinal meningiomas, and other spinal tumors.

Schwannomatosis

Schwannomatosis is the third major group of neurofibromatosis (sometimes "incorrectly" referred to as NF3). It is characterized by multiple nerve sheath tumors (called schwannomas) throughout the body that do not typically involve skin. These tumors are benign and usually occur along major peripheral nerves. They can have a daisy chain appearance on MRI. The condition typically presents in adulthood. A major differentiating factor is the absence of vestibular schwannomas, which are characteristic of NF2-related schwannomatosis (NF2).

Facial Manifestations of NF

Neurofibromatosis can involve virtually any part of the human body. When tumors arise on the face, they can be particularly difficult to treat. These tumors can cause severe facial distortions, in addition to impairing critical functions such as breathing, vision, speech, and hearing. Common facial manifestations include:

  • Plexiform neurofibromas on the face can be quite large, causing displacement of normal anatomy and interference with vision, facial movement, or hearing.
  • Eye involvement with neurofibroma can create a stark visual change by altering eye level or position of the eye socket itself. Optic gliomas can present frequently in NF1 patients and can alter vision and even push the eye forward.
  • Droopy eyelid and brow can occur due to the sheer mass of the tumor or by way of nerve infiltration and impairment.
  • Soft tissue excess occurs often as a result of certain chemical factors emitted by neurofibromas that can weaken the attachments that keep skin anchored in place, causing stretching. Redundant skin and subcutaneous tissues will need to be surgically tailored back to normal anatomy.
  • Facial asymmetry occurs when one side of the face is involved.
  • Facial nerve involvement occurs more frequently with NF2-related schwannomatosis (NF2). However, large NF1 tumors can either compress the nerve or physically overwhelm the anatomy, hiding underlying muscle movement.

There is a heavy psychological burden for patients exhibiting the facial manifestations of NF. Many patients experience social isolation, depression, and anxiety related to their appearance, which they cannot easily conceal. Surgery addresses not just the physical symptoms of neurofibromatosis but the emotional and social aspects as well.

Cover of Your Guide to Neurofibromatosis Surgery by Andre Panossian, MD
Complimentary Guide

What to Expect From Neurofibromatosis Surgery

A guide to surgical treatment for neurofibromatosis. This guide is written for patients and families trying to decide whether surgery is the right next step.

  • What NF1, NF2-related schwannomatosis (formerly NF2), and schwannomatosis each involve
  • When does surgery help, when does it not, and what realistically determines success
  • Why cutaneous and plexiform tumors are approached differently
  • Comparing electrodesiccation, surgical excision, and staged reconstruction
  • What is the recovery like
  • What to do if tumors continue to form after surgery
  • Questions to ask your surgeon before moving forward

We will email you the guide. No newsletter, no sharing your address. This is educational information, not medical advice.

What are the treatments for neurofibromatosis?

The majority of treatment for neurofibromatosis involves controlling symptoms and growth of tumors. Surgical excision and reconstruction are central to the treatment plan for patients. It is not uncommon to require several surgeries over the course of a lifetime to remove problematic tumors or to improve the appearance of the affected area. Multiple specialists may be required to treat tumors depending on the anatomy involved. Neurosurgeons, plastic surgeons, orthopedic surgeons, otolaryngologists, and ophthalmologists may need to address problems in specific organ systems.

For those individuals experiencing extensive small skin tumors, electrodesiccation is a good option for improving the contour of raised small masses. The process involves cauterizing the surface portions of cutaneous neurofibromas, which initially results in a small scab. Healing over the next 2 weeks will then result in the ingrowth of new skin and a flatter contour. Electrodesiccation does not necessarily remove the possibility of malignant tumors or prevent the regrowth of neurofibromas, but results are usually long-lasting. Dr. Panossian performs electrodesiccation under local anesthesia in the office for small areas of multiple tumors or in the operating room under general anesthesia. An alternative to this procedure is CO2 laser destruction which can be performed similarly under local or general anesthesia.

What role do MEK inhibitors play in the treatment of neurofibromatosis?

Over the last decade or so, advances in NF research have resulted in the identification of a class of medications that may slow or possibly prevent the growth of neurofibromas. These are known as MEK inhibitors (MAPK/ERK kinase or MAP2K inhibitors). Two specific MEK inhibitors, selumetinib (aka, Koselugo) and mirdametinib (aka, Gomekli), are now FDA-approved for NF1 plexiform neurofibromas that are not amenable to surgery. They work by interfering with the chemical signaling pathways responsible for cell growth and survival. MEK inhibitors are not chemotherapy. Instead, they specifically target certain cellular processes that are unique to tumors. Although a promising step forward in understanding and treating NF, the vast majority of patients with tumors that are easily accessible or superficial are still better served with traditional surgical removal whenever possible.

In addition, there are currently no specific guidelines for using these medications. How long should someone remain on the medication? When is the right time to start or to stop? What happens to tumor growth when a dose is missed or the treatment is discontinued? For the time being, it is still considered lifelong therapy. As with all medications or treatments, MEK inhibitors also have potential side effects. Most common are skin rashes and gastrointestinal issues such as diarrhea, nausea, and abdominal pain. Although these may be tolerable in most patients, the medications may need to be stopped if these side effects become intolerable. It is unpredictable what happens to NF tumors once the medication is stopped.

Why choose Dr. Panossian for treatment of neurofibromatosis?

Dr. Panossian has been treating children and adults with all variants of neurofibromatosis for two decades. He has an understanding of how neurofibromas can change the anatomy and how to restore the disfigurement produced. Neurofibromas are also extremely challenging to excise. Blood loss during surgery can be quite large, depending upon the size and location of neurofibromas. Therefore, it is imperative to know how much blood loss is tolerable and to know how to perform this task safely. Dr. Panossian rehearses his surgeries for each patient ahead of time and employs several measures during surgery to limit blood loss. He also works closely with his anesthesiologists at every step.

Complications can occur frequently following neurofibroma excision, including formation of a hematoma requiring drainage, infection, or wound separation. Scars can also be quite extensive. These are problems that can occur more regularly than other types of tumor excisions. Dr. Panossian has spent a large part of his career finding ways to limit the complications related to neurofibromatosis surgery. This includes limiting blood loss during and after surgery, placement of scars in concealed locations whenever possible, use of sterile technique, and implementation of reconstructive techniques with maximal preservation of normal nerve function.

Dr. Panossian is particularly interested in the efficient and safe removal of neurofibromas of all types and in all age groups. His subspecialty training in pediatric plastic surgery from the Hospital for Sick Children in Toronto, Canada is particularly helpful in complex reconstructive challenges in children with NF.

Raising NF Awareness

Raising awareness for NF is a top priority for Dr. Panossian. Many of his patients have shared their stories publicly, including on TLC's About Face.

NF Spotlight on National Television

Follow Dr. Panossian's patient on TLC's About Face, as she begins her surgical journey. Watch as this patient highlights some of the difficulties she faces as someone living with neurofibromatosis.

NF Advocacy in the Age of Social Media

Meet Dr. Panossian's patient, David. After years of self-isolation, David finally underwent extensive tumor excision. Hear his take on living with NF and what drives him to be an advocate for the NF community.

Frequently Asked Questions

Are neurofibromas cancerous?

The vast majority of neurofibromas are usually benign. However, some may present with signs that might suggest a malignant form of neurofibroma called a malignant peripheral nerve sheath tumor (MPNST). These signs include a rapidly growing mass, severe pain or tenderness, radiating or shooting pain downstream or upstream from the mass, ulceration, firmness (think of firm rubber or wood), and fixation to surrounding tissues with lack of skin mobility. These can be quite aggressive and require a different approach for removal and are best handled in unison with the surgeon and oncologist. Your doctor may have you get a new MRI or possibly perform an in-office biopsy (if superficial) to verify the diagnosis and determine its extent.

Wide surgical excision is still the mainstay of treatment, but coordination with a neuro-oncologist must occur to provide timely chemotherapy. Sometimes, radiation therapy may be required to control aggressive growth. If you are experiencing any unusual symptoms related to a particular neurofibroma, make sure to contact your neurologist, NF doctor, or primary care doctor immediately for evaluation.

Is there a cure for neurofibromatosis?

There is currently no known cure for neurofibromatosis. Surgery to remove tumors is not necessarily curative. Neurofibromatosis can affect virtually all nerves in the human nervous system. Therefore, surgically removing all of these tumors at once is not usually possible but periodic surgical intervention can help control the size and number of tumors that arise and to stay ahead of new tumor formation. Some tumors may not be amenable to removal due to their location such as the brain, around the heart, within the spinal canal, or behind the eyes. Luckily, as long as tumor growth and new symptoms are monitored closely, there is little reason to place an individual at risk by attempting surgical removal.

I always say, "There is something we can always do."

If you or your loved one has been diagnosed with neurofibromatosis, give Dr. Panossian's office a call today to book your consultation.

Request a Consultation

How insurance works for neurofibromatosis surgery

1. Plotkin SR, Messiaen L, Legius E, et al. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med. 2022;24(9):1967-1977.